|Title:||Derivatives of quinuclidine|
|Abstract:||Quinuclidine derivatives having the general formula (I) ##STR1## and geometrical isomers, enantiomers, diastereoisomers, racemates and/or acid addition salts thereof, wherein Z represents the group >CR.sup.1 R.sup.2 or two hydrogen atoms; and R.sup.1 and R.sup.2, which may be identical or different, are each alkyl, cyclopentyl, cyclohexyl, aryl, or diarylmethylol, or alkyl which is substituted by one or more aryl groups, or one of R.sup.1 and R.sup.2 may be hydrogen.|
|Inventor(s):||Fisher; Abraham (Holon, IL), Karton; Ishai (Ness-Ziona, IL), Heldman; Eliahu (Rehovot, IL), Levy; Aharon (Moshav Beith Hanan, IL), Grunfeld; Yona (Rehovot, IL)|
|Assignee:||State of Israel, represented by Prime Minister's Office, Israel (Ness-Ziona, IL)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Dosage form; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.